What are the key issues to consider when scaling up the process for active pharmaceutical ingredients?

Thread Content

The active pharmaceutical ingredient – the drug substance – its quality has a significant impact on the safety and efficacy of the medication. To ensure the production quality of pharmaceuticals and guarantee safe use of drugs by the public, it is necessary to pay attention to the GMP on-site management in the active pharmaceutical ingredient manufacturing facilities. GMP production workshops are of great significance for effectively implementing production quality management and producing high-quality drugs. And when preparing the production of active pharmaceutical ingredients to scale up from laboratory to industrial levels, it is necessary to pay attention to the potential problems that may arise during the scale-up of the manufacturing process for these ingredients. (1) Evaluation of the availability of raw material intermediates Before carrying out scale-up reactions, it is necessary to examine the composition of the raw material intermediates to determine whether the expected benefits can be achieved, as well as whether products with the desired yield and quality can be obtained. The evaluation of the availability of raw materials and intermediates should take into account a combination of two approaches: analytical testing and experimental verification ； The evaluation of raw materials is combined with the evaluation of intermediates. (2) Review of the manufacturing process route for the active pharmaceutical ingredient. Industrialization is the ultimate goal in the development of processes for active pharmaceutical ingredients, and when selecting a route, the primary consideration is whether it is possible to carry out mass production on an industrial scale. Under normal circumstances, the method for the unit reaction and the production process route should be basically determined at the laboratory stage. During the pilot-scale-up phase, the specific process operations and conditions are determined to suit industrial production. However, when a selected process route and process steps give rise to significant problems that are difficult to overcome during pilot-scale scaling up, it is necessary to review the laboratory process route and modify its process steps. (3) The process scaling route should avoid complexity as much as possible. In process development and scaling, simplicity is key, as the simpler it is, the fewer opportunities there are for process errors. In practice, the more complex a process is, the harder it is for operators to master, and it is also difficult to describe in detail through standard operating procedures. Simplification is not only for safety reasons, but it can also reduce the production cycle and minimize waste. Avoid reactions that require very special equipment, or those that are highly dangerous and necessitate safety measures, such as nitration and hydrogenation. The simplification of the process stems from the simplification of the reaction route; generally, the route with the fewest reaction steps is the better one. During the process development stage, it is necessary to consider whether it is possible to avoid the separation of intermediates, combine reactions, and reduce the types and quantities of solvents used. Medici is a CRO company dedicated to providing customers with fast and efficient services. Its unique research and development model for \"customized\" pharmaceutical manufacturing processes also reflects this philosophy, enabling customers to obtain the API at an early stage so as to carry out clinical studies. Medici’s process R&D department has extensive experience in optimizing processes and developing new, safe, and environmentally friendly process routes, and is committed to helping customers create processes that are stable, cost-effective, and suitable for large-scale production. (4) Equipment availability and selection of materials and types: When establishing a GMP production facility, effective GMP improvement techniques are applied during the drug manufacturing process to enhance the physical conditions of the facility. The pharmaceutical design department determines the actual level of production and identifies the GMP standards that must be met. The 2010 version of GMP has significantly raised the control requirements for the production of active pharmaceutical ingredients, especially sterile ones, and has also increased the requirements for manufacturing equipment. When scaling up the process for active pharmaceutical ingredients, it is necessary to consider the availability of the equipment. When evaluating the availability of such equipment, six points should be taken into account: whether the mixing condition meets the process requirements ； What is the minimum amount of solvent required for feeding into the reaction equipment? ； Does the heating medium have a temperature indicator and can it be controlled within the range required by the process? ； Can the temperature at the droplet formation point be controlled (whether the droplets reach a low enough temperature, whether they are sufficiently diluted, whether the location where droplets form is where mixing is strongest, and whether the distribution of droplets meets the process requirements, etc.) ； Has the reaction equipment achieved the required level of cleaning and drying according to the process specifications? ； Whether the reaction equipment meets the sealing requirements of the process. When starting pilot-scale scale-up, the material and type of various equipment required should be considered to determine their suitability, with particular attention paid to the selection of materials for equipment that comes into contact with corrosive substances. (5) Examination of mixer type and mixing speed: Most reaction processes in drug synthesis are heterogeneous reactions, which involve significant heat effects. In the laboratory, due to the small volume of the material and good mixing efficiency, problems related to heat and mass transfer are not apparent. However, when scaling up to pilot scale, these heat and mass transfer issues become prominent due to the effects of mixing efficiency. Therefore, during pilot-scale scaling up, it is necessary to consider the type of stirrer based on the properties of the materials and the characteristics of the reaction, and to examine the impact of stirring speed on the reaction behavior. Especially in solid-liquid heterogeneous reactions, it is important to select a stirrer type that meets the requirements of the reaction as well as an appropriate stirring speed. (6) Further study of reaction conditions: The optimal reaction conditions obtained at the laboratory stage may not meet the requirements for scale-up to pilot scale. In-depth experimental studies should be conducted on the main influencing factors, such as the feeding rate in exothermic reactions, the heat transfer area and coefficient of the reaction vessel, as well as the refrigerant, in order to understand their variation patterns in pilot-scale units and thus determine more suitable reaction conditions. (7) Determination of the process flow and operation methods: During the pilot-scale-up phase, as the amount of material to be processed increases, it becomes necessary to consider how the reaction and post-treatment processes can be adapted to meet the requirements of industrial production; particular attention should be paid to shortening the procedures and simplifying the operations. Avoid heating after adding all the ingredients, as well as heating without stirring; do not add solids to a reacting mixture that is under reflux or hot. This is a common operation in pilot tests, but difficult to implement in production. For those new to process scaling, the biggest surprise might be that all operations take a long time. It is important to conduct stability assessments for all raw materials, intermediates, and products prior to scaling up. Avoid reactions that require immediate quenching and separation after the reaction occurs. (8) Quality control of raw materials, auxiliary materials, and intermediates includes: (1) Determination of the physical properties and chemical parameters of raw materials, auxiliary materials, and intermediates ； (2) Formulation of quality standards for raw materials, auxiliary materials, and intermediates. Furthermore, it is important to avoid neglecting the issue of solvent use; in pilot tests, solvents with good solvating properties and that are easy to distill and recover may be used. But some of them need to be avoided in production. This includes all solvents of that category, those with a flash point below -18°C. (9) Do not ignore potential degradation reactions. Do not carry out the reaction at temperatures within 50°C, the known degradation temperature of the reactants, to avoid loss of control over the reaction. In addition to the calorimetric evaluation of exothermic reactions, self-accelerating degradation reactions also need to be examined. This requires additional experiments, such as adiabatic reaction calorimetry (ARC); if analysis suggests that the reaction may produce potentially unstable and prone-to-degradation products, corresponding calorimetric tests should be conducted. Some degradation reactions may proceed very slowly and cannot be detected by conventional tests. Even below the onset temperature, the exothermic reaction still increases at a slow rate; by the time a significant rise in temperature is detected, the decomposition reaction has already taken place. The preparation of active pharmaceutical ingredients can supply qualified materials for pharmacological and toxicological studies, formulation development, and clinical trials during the drug development process, as well as provide detailed information for quality assessments of drugs. Therefore, it is of great importance to have manufacturing processes for active pharmaceutical ingredients that are suitable for industrial production. The establishment of GMP production facilities for active pharmaceutical ingredients, along with the comprehensive improvement of the GMP management standards in these facilities, ensures the production of high-quality drugs.